派林生物(000403.SZ)：全资子公司获得药品补充申请受理通知书

Core Viewpoint - The company, Guangdong Shuanglin Biopharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for a supplemental application regarding intravenous immunoglobulin, which is expected to enhance clinical safety and convenience while aligning domestic product processes with international standards [1][2]. Group 1: Product Approval and Indications - The intravenous immunoglobulin is indicated for primary immunoglobulin deficiency diseases, secondary immunoglobulin deficiency diseases, and autoimmune diseases [1]. - The product utilizes advanced purification techniques, providing significant advantages in quality and virus safety, particularly in product yield [1]. Group 2: Clinical Trials and Competitive Position - Guangdong Shuanglin has received multiple approvals for clinical trials of intravenous immunoglobulin for various indications, including primary immune thrombocytopenic purpura (ITP) and chronic inflammatory demyelinating polyneuropathy (CIDP) [2]. - The company's diversified product development strategy is expected to enhance its competitive edge and improve the overall utilization rate of raw plasma, thereby increasing profitability [2].